Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-02-26 Earnings Release
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Earnings Release Classification · 95% confidence The document is a press release from argenx announcing positive topline results from a Phase 3 clinical trial (ADAPT OCULUS). It details the study's primary endpoint, statistical significance, and future regulatory plans (sBLA submission). This type of announcement, which focuses on clinical trial outcomes and drug development progress, is classified as a Regulatory Filing (RNS) within the provided schema, as it does not fit into specific categories like Earnings Release (which would focus on financial results) or Investor Presentation. Q1 2026
2026-02-26 English
argenx to Present at TD Cowen 46th Annual Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (under 5,000 characters) informing the public that a company executive will be presenting at an upcoming healthcare conference. It provides details on how to access the webcast but does not contain the presentation materials themselves. This fits the definition of a general regulatory announcement or a corporate event notification, which falls under the RNS (Regulatory Filings) category as a fallback for miscellaneous announcements that do not fit specific report types.
2026-02-23 English
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) notifying the public about an upcoming conference call to discuss financial results. It does not contain the financial results themselves, but rather serves as an invitation/announcement for the event. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-19 English
FORM 6-K
Foreign Filer Report
2026-01-13 English
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
Audit Report / Information Classification · 95% confidence The document is a press release from argenx announcing that the FDA has accepted a supplemental Biologics License Application (sBLA) for priority review. This is a standard corporate announcement regarding regulatory progress for a drug candidate. It does not fit into specific categories like 10-K, CT, or DVA. As it is a general regulatory announcement regarding company operations and product development, it falls under the 'Regulatory Filings' (RNS) category. Q1 2026
2026-01-13 English
FORM 6-K
Foreign Filer Report
2026-01-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.